

ENVIRONMENTAL PROTECTION AGENCY**[ER-FRL-9024-5]****Environmental Impact Statements; Notice of Availability**

Responsible Agency: Office of Federal Activities, General Information (202) 564-7146 or <http://www2.epa.gov/nepa>. Weekly receipt of Environmental Impact Statements
Filed 12/07/2015 Through 12/11/2015
Pursuant to 40 CFR 1506.9.

Notice

Section 309(a) of the Clean Air Act requires that EPA make public its comments on EISs issued by other Federal agencies. EPA's comment letters on EISs are available at: <http://cdxnodengn.epa.gov/cdx-nepa-public/action/eis/search>.

EIS No. 20150350, Draft, NMFS, FL, Regional Management of Recreational Red Snapper Amendment 39 to the Fishery Management Plan for the Reef Fish Resources in the Gulf of Mexico, Comment Period Ends: 02/01/2016, Contact: Roy E. Crabtree 727-824-5301.

EIS No. 20150351, Final, USFWS, TX, Southern Edwards Plateau Habitat Conservation Plan, Review Period Ends: 01/19/2016, Contact: Adam Zerrenner 512-490-0057.

EIS No. 20150352, Final, USFS, MT, Montanore Project, Review Period Ends: 01/19/2016, Contact: Lynn Hagarty 406-283-7642.

EIS No. 20150353, Draft, FRA, MD, Draft Section 4(f) Evaluation for the Baltimore & Potomac Tunnel Project, Comment Period Ends: 02/05/2016, Contact: Michelle W. Fishburne 202-293-0398.

EIS No. 20150354, Final, BR, CA, Upper Truckee River and Marsh Restoration Project, Review Period Ends: 01/19/2016, Contact: Rosemary Stefani 916-978-5045.

EIS No. 20150355, Final, USN, OR, Military Readiness Activities at Naval Weapons Systems Training Facility Boardman, OR, Review Period Ends: 01/19/2016, Contact: Amy Burt 360-396-0403.

EIS No. 20150356, Final, APHIS, PRO, Carcass Management During a Mass Animal Health Emergency, Review Period Ends: 01/19/2016, Contact: Lori P. Miller 301-851-3512.

Amended Notices

EIS No. 20150357, Adoption, NOAA, OR, ADOPTION—Southern Flow Corridor Project, Contact: Patricia A. Montanio 301-427-8600.

The U.S. Department of Commerce's National Oceanic and Atmospheric Administration (NOAA) is adopting the Federal Emergency Management Agency's FEIS #20150296, filed 10/22/2015 with EPA. NOAA was a cooperating agency for the above project, therefore recirculation of the document is not necessary under Section 1506.3(c) of the Council on Environmental Quality Regulations.

Dated: December 15, 2015.

Karin Leff,

Acting Director, NEPA Compliance Division, Office of Federal Activities.

[FR Doc. 2015-31903 Filed 12-17-15; 8:45 am]

BILLING CODE 6560-50-P**FEDERAL TRADE COMMISSION****[File No. 151-0048]****Drug Testing Compliance Group, LLC; Analysis To Aid Public Comment****AGENCY:** Federal Trade Commission.**ACTION:** Proposed consent agreement.

SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the draft complaint and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before January 13, 2016.

ADDRESSES: Interested parties may file a comment at <https://ftcpublic.commentworks.com/ftc/dtcgroup>

consent online or on paper, by following the instructions in the Request for Comment part of the **SUPPLEMENTARY INFORMATION** section below. Write “Drug Testing Compliance Group—Consent Agreement; File No. 151-0048” on your comment and file your comment online at <https://ftcpublic.commentworks.com/ftc/dtcgroupconsent> by following the instructions on the web-based form. If you prefer to file your comment on paper, write “Drug Testing Compliance Group—Consent Agreement; File No. 151-0048” on your comment and on the envelope, and mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW., Suite CC-5610 (Annex D), Washington, DC 20580, or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW., 5th Floor, Suite 5610 (Annex D), Washington, DC 20024.

FOR FURTHER INFORMATION CONTACT:

William Lanning (202-326-3361), Bureau of Competition, 600 Pennsylvania Avenue NW., Washington, DC 20580.

SUPPLEMENTARY INFORMATION: Pursuant to Section 6(f) of the Federal Trade Commission Act, 15 U.S.C. 46(f), and FTC Rule 2.34, 16 CFR 2.34, notice is hereby given that the above-captioned consent agreement containing consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC Home Page (for December 14, 2015), on the World Wide Web, at <http://www.ftc.gov/os/actions.shtm>.

You can file a comment online or on paper. For the Commission to consider your comment, we must receive it on or before January 13, 2016. Write “Drug Testing Compliance Group—Consent Agreement; File No. 151-0048” on your comment. Your comment—including your name and your state—will be placed on the public record of this proceeding, including, to the extent practicable, on the public Commission Web site, at <http://www.ftc.gov/os/publiccomments.shtm>. As a matter of discretion, the Commission tries to remove individuals' home contact information from comments before placing them on the Commission Web site.

Because your comment will be made public, you are solely responsible for making sure that your comment does not include any sensitive personal information, like anyone's Social Security number, date of birth, driver's license number or other state identification number or foreign country equivalent, passport number, financial account number, or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, like medical records or other individually identifiable health information. In addition, do not include any “[t]rade secret or any commercial or financial information which . . . is privileged or confidential,” as discussed in Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2). In particular, do not include competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices,